T
Tina Cascone
Researcher at University of Texas MD Anderson Cancer Center
Publications - 150
Citations - 6042
Tina Cascone is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 30, co-authored 97 publications receiving 3940 citations. Previous affiliations of Tina Cascone include Washington University in St. Louis & Seconda Università degli Studi di Napoli.
Papers
More filters
Journal ArticleDOI
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Journal ArticleDOI
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
Tina Cascone,Jodi A. McKenzie,Rina M. Mbofung,Simone Punt,Zhe Wang,Chunyu Xu,Leila Williams,Zhiqiang Wang,Christopher A. Bristow,Alessandro Carugo,Michael Peoples,Lerong Li,Tatiana Karpinets,Lu Huang,Shruti Malu,Caitlin Creasy,Sara E. Leahey E. Leahey,Jiong Chen,Yuan Chen,Helen Pelicano,Chantale Bernatchez,Y.N. Vashisht Gopal,Timothy P. Heffernan,Jianhua Hu,Jing Wang,Rodabe N. Amaria,Levi A. Garraway,Peng Huang,Peiying Yang,Ignacio I. Wistuba,Scott E. Woodman,Jason Roszik,R. Eric Davis,Michael A. Davies,John V. Heymach,Patrick Hwu,Weiyi Peng +36 more
TL;DR: It is demonstrated that tumor glycolysis is associated with the efficacy of ACT and the glycolynsis pathway is identified as a candidate target for combinatorial therapeutic intervention.
Journal ArticleDOI
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov,Monique B. Nilsson,Tina Cascone,Alexandra Briggs,Oddbjørn Straume,Oddbjørn Straume,Lars A. Akslen,Eugene Lifshits,Lauren Averett Byers,Li Xu,Hua Kang Wu,Pasi A. Jänne,Susumu Kobayashi,Balazs Halmos,Daniel G. Tenen,Xi M. Tang,Jeffrey A. Engelman,Beow Y. Yeap,Judah Folkman,Bruce E. Johnson,John V. Heymach +20 more
TL;DR: It is suggested that erlotinib resistance may be associated with a rise in both tumor cell and host stromal VEGF and that combined blockade of the VEGFR and EGFR pathways can abrogate primary or acquired resistance to EGFR TKIs.
Journal ArticleDOI
An integrin β 3 –KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
Laetitia Seguin,Shumei Kato,Aleksandra Franovic,M. Fernanda Camargo,Jacqueline Lesperance,Kathryn C. Elliott,Mayra Yebra,Ainhoa Mielgo,Andrew M. Lowy,Hatim Husain,Tina Cascone,Lixia Diao,Jing Wang,Ignacio I. Wistuba,John V. Heymach,Scott M. Lippman,Jay S. Desgrosellier,Sudarshan Anand,Sara M. Weis,David A. Cheresh +19 more
TL;DR: It is revealed that integrin αvβ3 serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib.
Journal ArticleDOI
CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-l1 blockade
Limo Chen,Lixia Diao,Yongbin Yang,Xiaohui Yi,B. Leticia Rodriguez,Y. Li,Y. Li,Pamela Villalobos,Tina Cascone,Xi Liu,Lin Tan,Philip L. Lorenzi,Anfei Huang,Qiang Zhao,Di Peng,Jared J. Fradette,David H. Peng,Christin Ungewiss,Jonathon D. Roybal,Pan Tong,Junna Oba,Ferdinandos Skoulidis,Weiyi Peng,Brett W. Carter,Youhong Fan,Caleb A. Class,Jingfen Zhu,Jaime Rodriguez-Canales,Masanori Kawakami,Lauren Averett Byers,Scott E. Woodman,Vassiliki A. Papadimitrakopoulou,Ethan Dmitrovsky,Jing Wang,Stephen E. Ullrich,Ignacio I. Wistuba,John V. Heymach,F. Xiao Feng Qin,F. Xiao Feng Qin,Don L. Gibbons +39 more
TL;DR: It is observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment, providing a novel mechanism of acquired resistance to immune checkpoint therapy.